Hypertension, end-stage renal failure on hemodialysis
Conditions
Interventions
Losartan group: Start with once-daily dosing of losartan 25-50 mg, and increase up to 50-100 mg if effect of losartan on the clinical parameters is insufficient. Target blood pressure is less than 140
Sponsors
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
Yokohama Minami-Kyosai Hospital, Kosaikai Asahi Hospital, Fujisawa Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who just started mainetenance hemodialysis for ESRD with blood pressure>=140/90.
Exclusion criteria
Exclusion criteria: Malignancy, acute myocardial infarction/unstable angina, collagen diseases, acute renal failure, severe liver disorder, history of hypersensitivity to the administered ARB, pregnant women, or women suspected of being pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Ambulatory BP monitering (mean BP, BP and HR variability) 2) UCG, carotid echogram (IVSd, LVDd, LVPWd, LVDs, FS, EF, E/A, DcT, LAD, IMT) 3) ABI/baPWV 4) Blood chemistry Endocrine: catecholamine, ANP, BNP, PRA, PAC Coagulation: fibrinogen Glucose: blood glucose, IRI Serological: CRP Oxidative stress: adiponectin, MDA-LDL, AGE | — |
Countries
Japan
Contacts
Public Contactkazuaki UCHINO
Yokohama City University School of Medicine Deaprtment of Cardiorenal Medicine
Outcome results
None listed